Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.94 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 7/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829032 | 0.84 | LMNA (0.69) | KMT2ALMNASMN1; SMN2MEN1HTT | |
| SCHEMBL949387 | 0.78 | DRD2 (0.79) | KMT2ALMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL17482339 | 0.78 | BCHE (0.69) | KMT2ALMNAMEN1HTTMAPK1 | |
| SCHEMBL11714770 | 0.77 | HTT (0.90) | KMT2ALMNAHTTHSD17B10ALDH1A1 | |
| SCHEMBL19766699 | 0.77 | HTT (0.90) | KMT2ALMNAHTTHSD17B10ALDH1A1 | |
| SCHEMBL6100075 | 0.75 | KMT2A (0.57) | KMT2ALMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL27563849 | 0.75 | TACR1 (0.57) | KMT2ASMN1; SMN2MAPTMEN1HTT | |
| SCHEMBL30064669 | 0.75 | KDM4E (0.67) | KMT2ALMNASMN1; SMN2MAPTMEN1 | |
| SCHEMBL11850453 | 0.74 | KMT2A (0.56) | KMT2ALMNAMEN1BCHE | |
| SCHEMBL9650859 | 0.74 | KMT2A (0.66) | KMT2ALMNASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | CD4, CD74, HAVCR2 | KMT2A 4731/4885LMNA 4015/4885SMN1; SMN2 4794/4885 |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CD4, CD74, HAVCR2 | KMT2A 4731/4885LMNA 4015/4885SMN1; SMN2 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.